A multimodal diagnostic package is designed to evaluate suspected cases of insulinoma. The package includes serum testing to detect elevated insulin and proinsulin levels during an episode of hypoglycemia, as well as measurement of pancreatic islet cell antibodies (ICA) and antiinsulin antibodies (IAA) to rule out autoimmune diseases that may mimic the symptoms of the tumor. The package aims to confirm a diagnosis of hyperinsulinemia of tumor origin and differentiate it from other causes of hypoglycemia, such as the use of diabetes medications or autoimmune disorders (autoimmune hypoglycemic syndrome)